A recently published report by Mordor Intelligence analyzes future projections, growth drivers and the key trends that are shaping the…
Publishing research in peer-reviewed journals plays a central role in ensuring the credibility and reliability of scientific findings. Companies that…
LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”). LB-100 helps in…
A team of scientists from Texas Children’s Hospital, University of Pittsburgh and Baylor College of Medicine has discovered the primary driver of…
In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability.…
Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that…
Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment. LIXTE’s…
Researchers seeking new ways of fighting cancer using immunotherapy have discovered a “hidden brake” that had previously been unknown to…
LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity…
On Tuesday this week, researchers revealed that a group of hackers linked to the Iranian government had targeted another United States medical institution…